Loading…
Thyrocare Technologies (THYROCARE)₹485.30−2.74%Healthcare Service Provider
Thyrocare Technologies is compared with the 8 closest in size in Healthcare Service Provider (37 companies in the industry). It has a P/E of 53.8 against a peer median of 53.8, and ROCE of 35.1% against a peer median of 21.0%, and latest-quarter sales growth of 24.8% against a peer median of 22.2%. By market cap it is #4 of 9 in this set.
As of · Peer set: 8 closest in size in Healthcare Service Provider
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 33,877 | 62.4 | 28.0 | 22.4 | 0.08 | 0.6 | 2,755 | 510 | 19.1 | 26.9 | vs THYROCARE |
| Vijaya Diagnostic Centre | 15,226 | 80.9 | 21.0 | 19.8 | 0.44 | 0.1 | 813 | 173 | 22.8 | 35.9 | vs THYROCARE |
| Metropolis Healthcare | 12,055 | 59.6 | 18.0 | 13.7 | 0.15 | 0.5 | 1,646 | 190 | 16.5 | 26.6 | vs THYROCARE |
| Thyrocare Technologies | 7,716 | 53.8 | 35.1 | 28.5 | 0.09 | 1.4 | 832 | 163 | 24.8 | −68.7 | — |
| Nephrocare Health Services | 6,238 | 147.3 | 15.0 | 8.8 | 0.07 | 0.0 | 998 | 77 | 23.7 | 33.4 | vs THYROCARE |
| Suraksha Diagnostic | 1,826 | 50.6 | 17.0 | 14.1 | 0.53 | 0.1 | 309 | 31 | 20.6 | 44.5 | vs THYROCARE |
| Krsnaa Diagnostics | 1,602 | 16.5 | 13.1 | 10.9 | 0.55 | 0.4 | 772 | 101 | 22.2 | −19.0 | vs THYROCARE |
| 3B Blackbio Dx | 1,110 | 20.0 | 24.9 | 19.8 | 0.01 | 0.4 | 142 | 60 | 50.6 | −29.1 | vs THYROCARE |
| Gaudium IVF and Women Health | 773 | 30.7 | 28.9 | 24.7 | 0.16 | 0.0 | 104 | 24 | 9.1 | −41.9 | vs THYROCARE |
| Peer median | 6,238 | 53.8 | 21.0 | 19.8 | 0.15 | 0.4 | 813 | 101 | 22.2 | 26.6 |
Listed companies closest to Thyrocare Technologies in Healthcare Service Provider include Dr. Lal Path Labs, Vijaya Diagnostic Centre, Metropolis Healthcare, Nephrocare Health Services, Suraksha Diagnostic, Krsnaa Diagnostics, 3B Blackbio Dx, Gaudium IVF and Women Health.
Dr. Lal Path Labs, with a market cap of ₹33,877 Cr.
Thyrocare Technologies trades at a P/E of 53.8; the median of its peer set is 53.8. A P/E above or below the median is a description, not a judgement on value.
Thyrocare Technologies' return on capital employed is 35.1%, above the peer median of 21.0%.